Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

according to a study published online Nov. 14 in the New England Journal of Medicine to coincide with the annual meeting of ...

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

Fate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in ...

There are multiple chapters near you. Select your preferred chapter.

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...